Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Intercell Receives CHMP Positive Opinion for the Pediatric Indication of IXIARO®

Published: Thursday, December 20, 2012
Last Updated: Wednesday, December 19, 2012
Bookmark and Share
Final approval is expected in February or March 2013.

Intercell AG has announced that the CHMP of the European Medicines Agency (EMA) has come to a positive opinion on the Marketing Authorization for IXIARO® in children, a vaccine to protect against Japanese Encephalitis (JE).

The final decision (approval) by the European Commission is expected in February or March 2013.

Intercell has submitted applications for the approval of a JE vaccine pediatric label extension to major regulatory agencies in late Q2 2012 based on data from a Phase III clinical study conducted in the Philippines and favorable interim data from a second Phase III trial in EU, US and Australia.

In both studies the JE vaccine showed to be highly immunogenic in children aged 2 months to <18 years with a safety profile comparable to pediatric vaccines licensed for other diseases.

“We are very pleased about the positive CHMP opinion on the pediatric indication for our JE vaccine. This will be the first time European travelers of all ages can be protected against this dreadful disease with a licensed vaccine", states Thomas Lingelbach, Chief Executive Officer of Intercell AG.

Following the approval and launch of Intercell's vaccine against Japanese Encephalitis for adult travelers and military personnel in Europe, the United States, Canada, Hong Kong, Singapore, Israel (IXIARO®) and Australia and New Zealand (JESPECT®), the development of a vaccine to protect children traveling to endemic areas from Japanese Encephalitis has been a major goal of the Company.

The vaccine to prevent Japanese Encephalitis (JE) is Intercell’s first product on the market. This is a next-generation vaccine used to help prevent infection with the JE virus, and has been licensed in more than 30 countries.

The vaccine is a purified, inactivated vaccine and causes the body to produce its own protection (antibodies) against this disease.

Upon approval of the new indication for the pediatric age segment in the EU, the vaccine will offer protection against JE for adults and children aged 2 months and above who travel to, or live in, endemic areas.

In the U.S. the vaccine is currently licensed for those above 17 years of age, and in Canada, Australia and New Zealand it is licensed for persons above 18 years of age.

In the U.S. the pediatric label extension is currently under review by the FDA.

The vaccine is manufactured by Intercell AG’s wholly-owned subsidiary Intercell Biomedical Ltd. at our cGMP facility in Livingston, Scotland.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Intercell and Vivalis Provide Update on the Progress Towards Intended Merger
Company’s general meetings have been convened and will take place on 27 February 2013 and 4 March 2013 respectively.
Wednesday, January 30, 2013
Thomas Szucs Elected New Chairman of Intercell’s Supervisory Board
Thomas Szucs takes over the function from Michel Gréco, who resigned from the role but still remains a member of the Supervisory Board.
Tuesday, January 03, 2012
Intercell Receives Positive Scientific Advice from EMA for Pseudomonas Vaccine Phase II/III-Study
First interim data are expected mid 2013.
Monday, October 17, 2011
Successful Completion of Investigational Japanese Encephalitis Vaccine Study
Intercell AG and its partner Biological E. Ltd. announce the successful completion of a pediatric Phase II/III study for the vaccine to protect children from Japanese Encephalitis (JE).
Saturday, September 17, 2011
Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study
Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.
Monday, October 25, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos